On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Herbert I. Hurwitz

ResearcherPublications, citations & collaboration network

Herbert I. Hurwitz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Herbert I. Hurwitz have?

ScholarIQindexed works

Herbert I. Hurwitz has 534 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Herbert I. Hurwitz have?

ScholarIQcitation count

Herbert I. Hurwitz has 35,840 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Herbert I. Hurwitz?

ScholarIQh-index

Herbert I. Hurwitz has an h-index of 80 in OpenAlex.

What is the i10-index of Herbert I. Hurwitz?

ScholarIQi10-index

Herbert I. Hurwitz has an i10-index of 229 in OpenAlex.

What is the ORCID of Herbert I. Hurwitz?

ScholarIQorcid

The ORCID for Herbert I. Hurwitz is on the source record.

What is the OpenAlex record for Herbert I. Hurwitz?

ScholarIQopenalex

The OpenAlex for Herbert I. Hurwitz is on the source record.

What are the most-cited papers on Herbert I. Hurwitz?

ScholarIQmost cited works
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L. Coleman, Regula Deurloo, Olivier Chinot
Cancer Treatment Reviews. 20201,153 Citations
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert I. Hurwitz, Federico Innocenti, Mary F. Mulcahy, Eileen M. O’Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg
Journal of Clinical Oncology. 2010845 CitationsOPEN ACCESS
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees, Afshin Dowlati, Kimberly Blackwell, Bert H. O’Neil, P. Kelly Marcom, Matthew J. Ellis, Beth Overmoyer, Suzanne F. Jones, Jennifer L. Harris, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Steve Mangum, Neil L. Spector
Journal of Clinical Oncology. 2005626 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account